4/9
07:30 am
ifrx
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
High
Report
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
3/31
07:30 am
ifrx
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
Medium
Report
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
3/30
07:30 am
ifrx
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
Medium
Report
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
3/20
08:44 am
ifrx
InflaRx (IFRX) had its price target lowered by Guggenheim from $22.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
InflaRx (IFRX) had its price target lowered by Guggenheim from $22.00 to $14.00. They now have a "buy" rating on the stock.
3/19
07:30 am
ifrx
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
Medium
Report
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
3/18
07:30 am
ifrx
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
Medium
Report
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
3/13
05:30 pm
ifrx
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement [Yahoo! Finance]
Medium
Report
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement [Yahoo! Finance]
3/13
05:00 pm
ifrx
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Medium
Report
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
3/12
07:30 am
ifrx
InflaRx to Report Full Year 2025 Results on March 19, 2026
Low
Report
InflaRx to Report Full Year 2025 Results on March 19, 2026
2/26
08:13 am
ifrx
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Low
Report
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
2/26
07:30 am
ifrx
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
Low
Report
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
1/29
07:30 am
ifrx
InflaRx Announces Participation in February Investor Conferences
Low
Report
InflaRx Announces Participation in February Investor Conferences